SEC Form 4 · accession 0001144204-16-140712
Edesa Biotech, Inc. · EDSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mayank D. Sampat
Director
Period of report
Dec 20, 2016
Accepted (ET)
Dec 21, 2016 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001540159
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $2.03 | Dec 20, 2016 | A | 2,500 | A | — | Dec 20, 2023 | Common Shares | 2,500 | 2,500 | D |
Explanation of responses
- F1Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third immediately, as to one-third on December 20, 2017 and as to the remaining one-third on June 20, 2018.